浙江联盛化学股份有限公司 董事会秘书工作细则 浙江联盛化学股份有限公司 董事会秘书工作细则 第一章 总 则 第一条 为了促进浙江联盛化学股份有限公司（以下简称"公司"）规范化 运作，充分发挥董事会秘书的作用，加强董事会秘书工作的指导，根据《中华人 民共和国公司法》（以下简称《公司法》）、《中华人民共和国证券法》（以下 简称《证券法》）、《深圳证券交易所创业板股票上市规则》（以下简称《股票 上市规则》）《深圳证券交易所上市公司自律监管指引第2号——创业板上市公 司规范运作》等法律法规、规范性文件以及《浙江联盛化学股份有限公司章程》 （以下简称《公司章程》）的有关规定，制定本细则。 第二条 公司设董事会秘书一名，由公司董事、副总经理、财务负责人或者 《公司章程》规定的其他高级管理人员担任，对公司和董事会负责，负责公司股 东会和董事会会议的筹备、文件保管以及公司股东资料的管理，办理信息披露事 务等事宜，为信息披露事务负责人。 第三条 董事会秘书应当遵守《公司章程》，承担法律法规及《公司章程》 对公司高级管理人员所要求的义务，享有相应的工作职权，并获取相应报酬，对 公司负有忠实和勤勉义务，不得利用职权为自己或者他人谋 ...

浙江联盛化学股份有限公司 董事和高级管理人员所持本公司股份及其变动管理制度 浙江联盛化学股份有限公司 董事和高级管理人员 所持本公司股份及其变动管理制度 第一章 总 则 第一条 为加强浙江联盛化学股份有限公司（以下简称"公司"）对董事和 高级管理人员所持本公司股份及其变动的管理工作，根据《中华人民共和国公司 法》（以下简称《公司法》）、《中华人民共和国证券法》（以下简称《证券法》）、 《上市公司收购管理办法》《上市公司股东减持股份管理暂行办法》《上市公司 董事和高级管理人员所持本公司股份及其变动管理规则》《深圳证券交易所上市 公司自律监管指引第 10 号——股份变动管理》《深圳证券交易所上市公司自律 监管指引第 18 号——股东及董事、高级管理人员减持股份》等法律法规、规范 性文件以及《浙江联盛化学股份有限公司章程》（以下简称《公司章程》）的有 关规定，并结合公司实际情况，制定本制度。 第 1 页 共 7 页 浙江联盛化学股份有限公司 董事和高级管理人员所持本公司股份及其变动管理制度 第七条 公司董事、高级管理人员在买卖本公司股份前，应当将其买卖计划 以书面方式通知董事会秘书，董事会秘书应当核查公司信息披露及 ...

Core Viewpoint - Liansheng Chemical has shown a stable performance in terms of financing and stock trading, with significant growth in revenue and net profit year-on-year, indicating a positive outlook for the company. Financing and Trading Summary - On October 13, Liansheng Chemical's stock rose by 0.69%, with a trading volume of 38.83 million yuan. The financing buy-in amount was 5.03 million yuan, while the financing repayment was 3.98 million yuan, resulting in a net financing buy-in of 1.06 million yuan. The total financing and securities balance reached 53.86 million yuan, accounting for 1.89% of the circulating market value, which is above the 90th percentile of the past year, indicating a high level of financing activity [1]. - The company had no short-selling activity on October 13, with both short-selling repayment and sales at 0 shares, leading to a short-selling balance of 0 yuan, also above the 90th percentile of the past year, indicating a lack of short-selling interest [1]. Business Performance Summary - As of June 30, Liansheng Chemical had 8,697 shareholders, an increase of 2.52% from the previous period. The average number of circulating shares per person was 10,779, which increased by 238.68% [2]. - For the first half of 2025, Liansheng Chemical reported a revenue of 343 million yuan, representing a year-on-year growth of 13.95%. The net profit attributable to the parent company was 18.02 million yuan, reflecting a year-on-year increase of 9.61% [2]. Dividend Summary - Since its A-share listing, Liansheng Chemical has distributed a total of 97.52 million yuan in dividends. Over the past three years, the cumulative dividend payout has been 75.38 million yuan [3].

Core Viewpoint - Liansheng Chemical (301212.SZ) specializes in wet electronic chemicals, with products such as GBL, NMP, and IPA, which are used in manufacturing processes for display panels, semiconductors, and solar cells [1] Product Application - The company's products are involved in critical manufacturing processes including development, etching, and cleaning [1] - Currently, there is no direct collaboration with end solar energy storage customers, and it is suggested to monitor disclosures from downstream sectors for potential applications [1]

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has issued a warning to Liansheng Chemical and its executives due to violations related to idle fundraising and financial management practices [1][2] Group 1: Regulatory Actions - The Zhejiang Securities Regulatory Bureau decided to issue warning letters to Liansheng Chemical and its executives, including Chairman Mou Jianyu and General Manager Yu Kuai, for mismanagement of idle fundraising [1] - The violations included purchasing financial products before the authorized review period and exceeding the authorized amount [1] - The responsible individuals will have their actions recorded in the securities and futures market integrity archives [1] Group 2: Company Overview - Liansheng Chemical, established in October 2007, is a high-tech enterprise in the specialty fine chemical sector, listed on the Growth Enterprise Market in April 2022 [2] - The company's products are widely used in pharmaceuticals, pesticides, electronic chemicals, cosmetics, and emerging fields like semiconductors and lithium batteries [2] Group 3: Financial Performance - In the first half of 2025, Liansheng Chemical reported total revenue of 343 million yuan, a year-on-year increase of 13.95% [2] - The net profit attributable to shareholders was 18.02 million yuan, up 9.61% year-on-year, while the net profit after deducting non-recurring gains and losses was 16.04 million yuan, an increase of 11.35% [2] - The company experienced a significant improvement in cash flow, with a net cash flow from operating activities of 50.66 million yuan, compared to a negative 109 million yuan in the same period last year [2] Group 4: Profitability Trends - Liansheng Chemical has seen a continuous decline in both sales gross margin and net margin over the recent three semi-annual reports [2] - The sales gross margins for the first half of 2023, 2024, and 2025 were 22.21%, 13.33%, and 12.67% respectively, while the net margins were 14.67%, 5.72%, and 5.42% [2]

Group 1 - The core viewpoint of the news is that Liansheng Chemical experienced a decline in stock price and significant changes in financing activities on September 18, with a net financing outflow of 449.16 thousand yuan [1] - On September 18, Liansheng Chemical's stock price fell by 3.21%, with a trading volume of 41.93 million yuan [1] - The total financing and securities balance for Liansheng Chemical as of September 18 is 47.11 million yuan, which accounts for 1.66% of its market capitalization, indicating a high level compared to the past year [1] Group 2 - As of June 30, Liansheng Chemical had 8,697 shareholders, an increase of 2.52% from the previous period, with an average of 10,779 circulating shares per person, up by 238.68% [2] - For the first half of 2025, Liansheng Chemical reported a revenue of 34.3 million yuan, representing a year-on-year growth of 13.95%, and a net profit attributable to shareholders of 18.02 million yuan, up by 9.61% [2] Group 3 - Since its A-share listing, Liansheng Chemical has distributed a total of 97.52 million yuan in dividends, with 75.38 million yuan distributed over the past three years [3]

Core Viewpoint - Liansheng Chemical (301212.SZ) has received a regulatory letter from the Shenzhen Stock Exchange due to violations related to the management of idle raised funds, but the company claims that this issue has not affected its daily operations [1][2]. Group 1: Regulatory Issues - The company has been found to have multiple violations in its management of idle raised funds, including purchasing financial products before the approval period and exceeding the authorized purchase amount [2]. - Key personnel, including the chairman and general manager, have also faced regulatory measures for failing to fulfill their duties and obligations [2]. Group 2: Fundraising and Investment Projects - Liansheng Chemical was listed on the Shenzhen Stock Exchange in April 2022, raising a total of 8.01 billion yuan, with net proceeds of 7.27 billion yuan after deducting issuance costs [3]. - The raised funds are primarily allocated to two major projects aimed at expanding the company's business scale and improving production efficiency, with expected production commencement in mid-2026 [3]. Group 3: Financial Performance - Since its listing, the company has experienced significant fluctuations in its financial performance, with 2022 revenues of 1.041 billion yuan, a 24.98% increase year-on-year, and a net profit of 183 million yuan, up 106.69% [4]. - However, revenues declined to 662 million yuan in 2023, a 36.41% decrease, and further dropped to 632 million yuan in 2024, reflecting ongoing challenges in the market [4][5]. - The first half of 2025 showed signs of recovery, with revenues of 343 million yuan, a 13.95% increase, and a net profit of 18 million yuan, up 9.61% [4][5]. Group 4: Industry Context - The chemical industry is facing challenges such as intensified competition, rising raw material costs, and insufficient effective demand, which have contributed to the company's recent performance issues [5]. - Despite a slight recovery in the first half of 2025, the overall industry remains under pressure, with a reported 1.4% increase in revenue but a 9.0% decrease in profit for the chemical raw materials and products manufacturing sector [5].

Core Viewpoint - Zhejiang Liansheng Chemical Co., Ltd. faced regulatory scrutiny for violations related to information disclosure and improper use of raised funds, resulting in a warning letter from the China Securities Regulatory Commission [1] Group 1: Regulatory Violations - The chairman, general manager, and non-independent directors of the company were found to have violated information disclosure regulations and failed to fulfill other responsibilities [1] - The company was discovered to have invested idle raised funds in financial products before the authorized review period and exceeded the authorized investment amount [1] Group 2: Financial Reporting Issues - The special reports on the use of raised funds for the first half of 2023, the full year of 2023, the first half of 2024, and the full year of 2024 contained inaccurate disclosures regarding the purchase of large time deposits [1] Group 3: Regulatory Actions - The regulatory authority issued a warning letter as a supervisory measure, which will be recorded in the securities and futures market integrity file [1]

Core Points - Liansheng Chemical (301212.SZ) received a warning letter from the Zhejiang Securities Regulatory Bureau due to violations related to the management and use of raised funds [1][2] - The company was found to have purchased financial products with idle raised funds before the authorization period and exceeded the authorized amount [1] - The special reports on the use of raised funds for the first half of 2023, the full year of 2023, the first half of 2024, and the full year of 2024 contained inaccurate disclosures regarding the purchase of large time deposits [1] Regulatory Violations - The company's actions violated the "Regulatory Requirements for the Management and Use of Raised Funds by Listed Companies" and the "Administrative Measures for Information Disclosure of Listed Companies" [2] - Key executives, including the chairman, general manager, former financial director, and board secretary, were held primarily responsible for the violations [2] - The Zhejiang Securities Regulatory Bureau decided to issue warning letters to the company and the related personnel, which will be recorded in the integrity archives of the securities and futures market [2]

Core Viewpoint - Zhejiang Liansheng Chemical Co., Ltd. received a warning letter from the Zhejiang Securities Regulatory Bureau due to violations related to the management and use of raised funds [1][2] Group 1: Regulatory Violations - The company was found to have purchased financial products with idle raised funds before the authorization period and exceeded the authorized amount [1] - The special reports on the use of raised funds for the first half of 2023, the full year of 2023, the first half of 2024, and the full year of 2024 contained inaccurate disclosures regarding the purchase of large time deposits [1][2] Group 2: Responsible Parties - The chairman, general manager, former financial director, and board secretary of the company were held primarily responsible for the violations [2] - The violations were against the regulations outlined in the "Guidelines for the Supervision of Listed Companies on the Management and Use of Raised Funds" and the "Administrative Measures for Information Disclosure of Listed Companies" [2]